Home > Patients > Current Clinical Trials

Clinical Trials

NovaDigm conducted a clinical trial of its NDV-3A vaccine in patients diagnosed with recurrent vulvovaginal candidiasis (RVVC). The clinical trial studied the effect of a single dose of NDV-3A (compared to a placebo) in preventing future episodes of vulvovaginal candidiasis (VVC) in these patients. Safety and tolerability of the vaccine were also evaluated. The trial was conducted at multiple locations throughout the United States. To find out more about this study, please visit clinicaltrials.gov and search for study NCT01926028 and see our press release.